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HIV-1 transcytosis has been proposed as a potential mechanism allowing the virus to cross the epithelium during mucosal transmission.
Epitopes of the HIV-1 envelope involved in this process have not been identified yet. Here, we assessed a large panel of HIV neutralizing
antibodies recognizing well-characterized epitopes of the HIV-1 envelope for their ability to block HIV-1 transcytosis across a confluent epithelial
monolayer.
We found that all of the 13 HIV-1-specific monoclonal antibodies tested in the present study, including the three broadly neutralizing antibodies
2F5, 2G12 and IgG1b12, lacked the ability to inhibit transcytosis of cell-free and cell-associated R5- as X4-tropic HIV-1 across a tight and
polarized monolayer of HEC-1 epithelial cells. In contrast, anti-gp160 polyclonal antibodies purified from serum or breast milk of HIV-1-infected
individuals potently inhibited HIV-1 transcytosis. Furthermore, polymeric S-IgA exhibited similar ability to inhibit transcytosis compared to IgG
despite their lower anti-gp160 specific activity. Together, these results demonstrate that the major neutralizing envelope epitopes of HIV-1 are not
involved in HIV-1 transcytosis, and suggest that surface agglutination of virus particles may participate to the blocking effect observed with both
polyclonal and polymeric anti-gp160 immunoglobulins.
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Human immunodeficiency virus type 1 (HIV-1) is primarily
transmitted via mucosae (Van de Perre, 1999; Yeaman et al.,
1998). Several in vitro models have been developed to study the
mechanisms involved in the transmucosal passage of the virus
(Bomsel, 1997; Shattock et al., 2000). Transcytosis of HIV-1
through a tight monolayer of epithelial cells, such as human
endometrial carcinoma (HEC-1) cells, has been used to evaluate⁎ Corresponding author. Université Paris V, Unité INSERM Internationale
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virus and mucosal epithelial cells, as well as the intracellular
transport of HIV from the apical to the basolateral pole of the
monolayer (Bomsel, 1997). Both cell-free and cell-associated
viruses are able to cross transformed and primary epithelial cells
monolayers (Kage et al., 1998; Meng et al., 2002). Transcytosis
of HIV-1 does not occur at 4 °C (Hocini et al., 2001) and
is affected by inhibitors of the microtubular activity like
colchicine, indicating that this phenomena is an active process.
The early steps of the transcytosis process involve specific
surface molecules of the virus and epithelial cells. Thus,
galactosylceramide (GalCer), one of the alternative receptors
for HIV-1 on CD4-negative epithelial cells (Fantini et al., 1993;
Yahi et al., 1992), interacts with a conserved epitope on the DIII
determinant of gp41 in the initiation of transcytosis (Alfsen and
Table 1
Neutralizing activity of 13 monoclonal antibodies directed to well-defined epitopes of the HIV-1 envelope, on peripheral blood lymphocytes infected by various strains
of HIV-1 a
HIV-1 strains
Ba-L JR-CSF NDK VN44 Lai
TCLA/R5 c Primary/R5 Primary/X4 Primary/X4 TCLA/X4
Monoclonal antibodies to HIV-1 2F5 Human, IgG3κ b gp41 d 60.8 (7.4)a 60.3 (3.8) 39.3 (12.2) 42.3 (11.2) 96.2 (4.7)
2G12 Human, IgG1κ gp120 (V3–V4) 74.1 (7.9) 90.3 (9.1) 59.7 (19.1) 48.0 (14.9) 51.6 (5.2)
IgG1b12 Human, IgG1κ gp120 (CD4 BS) 98.6 (2,6) 97.0 (4.5) 65.6 (14.7) 77.4 (9.9) 98.5 (0.3)
17b Human gp120 (CD4i) 43.4 (8.8) 41.2 (8.2) −0.9 (1.0) 47.6 (6.5) 91.2 (2.1)
48d Human, IgG1κ gp120 (CD4i) 44.0 (10.3) 58.4 (14.1) −35.0 (0.6) −36.0 (5.1) 8.5 (11.2)
IIIB-V3-21 Mouse, IgG1 gp120 20.3 (6.5) −8.6 (14.5) 15.1 (6.2) −1.0 (3.5) 17.8 (4.8)
F105 Human, IgG1κ gp120 (CD4 BS) 40.4 (8.1) 28.7 (6.6) 17.9 (8.8) 49.5 (6.5) −65.9 (17.4)
5F3 Human, IgG1κ gp41 38.4 (19.0) 29.5 (39.0) 8.2 (7.3) 9.8 (0.5) 54.1 (0.7)
F240 Human, IgG1κ gp41 48.6 (11.4) 40.0 (3.0) 13.3 (2.5) 8.7 (2.3) 60.5 (10.8)
1577 Mouse gp41 19.5 (5.5) 33.0 (15.3) 5.1 (3.5) 22.2 (0.8) 34.2 (0.3)
F425B4a1 Human gp120 (V3) 33.5 (3.6) 38.7 (2.9) 16.9 (7.6) 16.4 (18.5) 33.8 (2.7)
F425A1g8 Human, IgG1λ gp120 (CD4i) 36.9 (3.6) 43.3 (6.1) 17.3 (11.1) 20.6 (13.5) 50.4 (9.5)
F425B4e8 Human, IgG2κ gp120 (V3) 47.0 (9.4) 42.6 (3.9) 49.6 (14.4) 35.8 (1.0) 18.2 (1.3)
a Results indicate the percentages of inhibition provided by 20 μg/ml of monoclonal antibodies, calculated by reference to the control experiment with irrelevant IgG
(no inhibition). Neutralization was quantified by p24 antigen release. Standard deviations are in brackets. Results of monoclonal antibodies giving significant
inhibition are indicated in bold.
b Species and isotype of antibodies.
c Phenotypic characteristics of viral strains [primary or TCLA (T Cell Line Adapted) strains; R5- or X4-tropism].
d Main recognized epitopes on HIV-1 surface. CD4 BS: CD4 binding site; CD4i: CD4 induced.
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epitopes are also required for the early steps of transcytosis, as
demonstrated by the ability of polyclonal antibodies to gp160 to
block HIV-1 transcytosis (Hocini et al., 2001). The latter
observation has allowed to use transcytosis assays as a mean to
functionally assess HIV-specific antibodies in the saliva (Devito
et al., 2000), cervicovaginal secretions (Belec et al., 2001;
Devito et al., 2000) and breast milk (Alfsen et al., 2001; Becquart
et al., 1999, 2000) in HIV-1-infected individuals. Using this
assay, HIV-specific antibodies purified from cervicovaginal
fluids in a minority of highly exposed, persistently HIV-
seronegative female sex workers have been shown to inhibit
transcytosis, suggesting that these antibodies play a role in the
protection against sexual acquisition of the virus in vivo (Belec
et al., 2001; Devito et al., 2000).
In the present study, we have investigated the inhibitory
activity on transcytosis of a large panel of monoclonal an-
tibodies directed to well-defined epitopes of the HIV-1
envelope, including the 3 broadly neutralizing antibodies 2F5,
2G12 and IgG1b12, to investigate whether target epitopes for
neutralizing antibodies on HIV-1 are also involved in inhibition
of transcytosis. Our results indicate that transcytosis of HIV-1
through epithelial cells involves distinct molecular mechanisms
than those occurring during infection of peripheral blood mono-
nuclear cells.
Results
Neutralization experiments
We used a single dose of antibody to assess the neutralizing
properties of monoclonal antibodies towards infection of PBLswith various strains of HIV-1. Virus was pre-incubated with
monoclonal antibody at a final concentration of 20.0 μg/ml for
1 h at 37 °C. A reduction in infectivity of at least 33% was
considered as significant. Under these conditions, the highest
neutralization titers were obtained with monoclonal antibodies
2F5, 2G12 and IgG1b12 (Table 1). Antibodies directed against
the CD4i epitope (17b and 48d) showed higher neutralizing
activities against R5- than against X4-strains. HIV-1Lai
was efficiently neutralized (reduction in infectivity superior to
90%) by three monoclonal antibodies IgG1b12, 2F5 and 17b,
whereas HIV-1NDK and HIV-1VN44, two primary X4-strains,
were relatively resistant to neutralization, with IgG1b12 ex-
hibiting the highest neutralizing activities of 65.6% and 77.4%,
respectively.
Transcytosis of HIV-1
We measured the relative ability of six HIV-1 strains as free
virus and of four HIV-1 strains as cell-associated virus, to cross
a tight monolayer of HEC-1 cells. Transcytosis was assessed by
p24 antigen quantification in the basal chamber after 4 h, 24 h
and 48 h. Transcytosis of cell-free virus at 4h ranged from
0.05% for HIV-1Ba-L to 0.49% for HIV-1Lai (Fig. 1). After 48 h,
this percentage reached 2.9% for HIV-1Lai. No transcytosis was
observed with cell-free HIV-1BruΔenv. All viral strains tested for
transcytosis efficiently replicated in PBMC, with the exception
of HIV-1BruΔenv (data not shown).
Transcytosis of cell-associated virus was assessed by mea-
suring p24 antigen concentrations in the apical (neo-produced
virions) and basal (transcytosed virions) chambers after 4 h and
24 h. Transcytosis of cell-associated virus ranged between 0.35%
for HIV-1VN44 and 0.75% for HIV-1Lai at 4 h (Fig. 2).
Fig. 2. Transcytosis of four HIV-1 strains in the form of cell-associated virus at
4 h and 24 h. Freshly isolated PBMC from seronegative donors were infected
with the indicated virus and deposited in the apical chamber. Virus was
quantified by p24 antigen ELISA. Results were expressed as percentage of virus
recovered in the basal chamber as compared with the amount of virus produced
in the apical chamber. The data are expressed as means±standard deviation
obtained in four independent experiments.
Fig. 1. Transcytosis efficiency through HEC-1 cells of eight strains of HIV-1 in the form of cell-free virus at 4 h, 24 h and 48 h. Results are expressed as percentage of
virus recovered in the basal chamber as compared to the amount of virus deposited in the apical chamber (5 ng). The data are expressed as means±standard deviation
obtained in four independent experiments.
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Each monoclonal antibody from our panel was tested for its
ability to block HIV-1 transcytosis. Cell-free virus was pre-
incubated with monoclonal antibodies (up to 50 μg/ml) or with
purified polyclonal anti-gp160 antibodies (positive control),
and deposited on the apical surface of HEC-1 cells. Four viral
strains capable of transcytosis as cell-free or cell-associated
virus (HIV-1JR-CSF, HIV-1NDK, HIV-1VN44 and HIV-1Lai) were
tested in combination with each monoclonal antibody.
None of tested monoclonal antibodies inhibited transcytosis
of cell-free HIV-1 (Fig. 3). Several antibodies increased the
passage of cell-free HIV-1 through HEC-1 cells. As depicted in
Fig. 3, F105 (which recognizes the binding site for HIV on
CD4) significantly increased transcytosis of HIV-1JR-CSF and
HIV-1VN44 (−53.8% and −27.6%, respectively). Moreover, the
mixture of the 13 monoclonal antibodies (50 μg/ml each)
did not inhibit HIV-1 transcytosis. Transcytosis of all viral
strains tested was however blocked by polyclonal anti-gp160
antibodies.
In order to assess whether surface agglutination of virus
particles by HIV-specific antibodies may be important to
observe HIV transcytosis inhibition, we incubated during
15 min at room temperature the mixture of the 11 human
monoclonal antibodies (10 μl at 50 μg/ml each) with cell-free
HIV-1JR-CSF, and after anti-human γ chain (10 μl at 2.5 mg/ml)
was added before the transcytosis assay. Polycloclonal anti-
gp160 was used as control. The transcytosis was then partially
inhibited by 45.2% when the mixture of monoclonal antibodies
and HIV-1JR-CSF was incubated with polyclonal anti-human γ
chain, whereas a 90%-inhibition was observed with polyclonal
anti-gp160 antibody. This observation clearly confirms that
agglutination of viral particles at the apical surface of the HEC-1
monolayer may be critical to obtain HIV transcytosis inhibition
by HIV-specific antibodies.
Similar experiments were further carried out with cell-
associated HIV-1 (Fig. 4). In such experiments, cells were notpre-incubated with monoclonal antibodies, but both antibodies
and cells were deposited on the apical surface of HEC-1 cells at
the same time, in order to minimize the amount of neo-produced
cell-free viral particles. As previously observed with cell-free
virus, all monoclonal antibodies tested as well as the mixture of
the 13 monoclonal antibodies did not inhibit transcytosis at 4 h.
The concentration of p24 antigen in the basal chamber was
lower at 24 h and 48 h due to the reduction of viral production in
the apical compartment, rather than to inhibition of transcytosis.
Purified polyclonal antibodies to gp160 significantly inhib-
ited the transcytosis process. Inhibition of transcytosis of cell-
associated virus by polyclonal antibodies to gp160 was always
lesser than inhibition of transcytosis of the corresponding virus
Fig. 3. Inhibition of transcytosis of cell-free HIV-1 through a tight HEC-1 epithelial barrier by 13 monoclonal antibodies and polyclonal antibodies to gp160. Free virus
(5 ng of HIV-1JR-CSF, HIV-1NDK, HIV-1VN44 and HIV-1Lai) was pre-incubated for 1 h with the indicated antibody (50 μg/ml) and added to the apical medium overlying
the monolayer of epithelial cells. Transcytosis was measured by quantitating p24 antigen in the basal medium after 4 h incubation. The results are expressed as means±
standard deviation of the percentages of transcytosis inhibition obtained in four separate experiments. IvIg: irrelevant IgG; Abmix: Mix of the 13 monoclonal
antibodies; Poly: Poyclonal anti-gp160 antibodies.
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versus 92% for HIV-1NDK, 59% versus 78% for HIV-1VN44 and
88% versus 94% for HIV-1Lai). Transcytosis of cell-free
HIV-1JR-CSF was inhibited by purified polyclonal antibodies to
gp160 in a dose-dependent manner (data not shown).
Inhibition of HIV-1 transcytosis by S-IgA and IgG purified from
breast milk
We further tested the ability of S-IgA and IgG purified from
breast milk from HIV-1-infected mothers demonstrating high
titers of anti-gp160 antibodies, to inhibit transcytosis of cell-associated virus. The addition of purified S-IgA and IgG to
HIV-1Lai-infected cells (1.0 μg/2×10
6 cells) on the apical pole
of the epithelial monolayer resulted in significant inhibition of
transcytosis. The inhibitory activity of S-IgAwas similar to that
of IgG on a weight basis, although S-IgA exhibited a lower anti-
gp160-specific activity than that of IgG (Fig. 5).
Discussion
None of the 13 HIV-specific monoclonal antibodies tested in
the present study, including the three broadly neutralizing
antibodies 2F5, 2G12 and IgG1b12, exhibited inhibitory
Fig. 4. Inhibition of transcytosis of cell-associated HIV-1 through a tight HEC-1 epithelial cells monolayer by 13 monoclonal antibodies and polyclonal antibodies to
gp160. Infected PBL (2×106 cells infected by HIV-1JR-CSF, HIV-1NDK, HIV-1VN44 or HIV-1Lai) were deposited on the apical surface of monolayer of HEC-1 cells with
HIV-specific antibody (50 μg/ml). Transcytosis was assessed as depicted in the legend of Fig. 3. IvIg: irrelevant IgG; Abmix: Mix of the 13 monoclonal antibodies.
Poly: Poyclonal anti-gp160 antibodies.
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as X4-tropic HIV-1 through a tight and polarized monolayer of
HEC-1 epithelial cells. Pooling the antibodies did not result in
any inhibitory activity either. All 9 monoclonal antibodies
known to be neutralizing prevented HIV replication in PBL. As
previously shown (Hocini et al., 2001), purified serum
polyclonal IgG antibodies to gp160 lead to a potent inhibition
of transcytosis of cell-free and cell-associated R5- as X4-tropic
HIV. Taken together, these results suggest that the major
envelope epitopes involved in neutralization are not involved in
mediating HIV transcytosis. The data further indicate that the
molecular basis of the transcytosis process of HIV-1 through
epithelial cells differs from that of infection of PBMCs with
HIV-1.Transcytosis of cell-free and cell-associated HIV-1 through
an epithelial cell monolayer is an active and specific process
implying viral envelope glycoproteins (Bomsel, 1997; Hocini
et al., 2001). Thus, we first observed that HIV-1 mutant lacking
envelope glycoproteins (Δenv) was not capable of transcytosis
through HEC-1 cells. We also confirmed previous reports
showing that the efficacy of transcytosis is independent of HIV
tropism (Hocini et al., 2001). For example, HIV-1Ba-L (R5-
tropic) and HIV-189.6 (R5- and X4-tropic) were not able to
transcytose through epithelial cells despite their ability to infect
CD4-positive lymphocytes and macrophages. Taken together,
these findings suggest that transcytosis could depend on amino-
acid sequences of gp160, likely not implicated in viral tropism.
Hence, the amino-acid sequences in variable domains of gp160
Fig. 5. Transcytosis inhibition provided by secretory-IgA (S-IgA; 1 μg, colored
bars) and IgG (1 μg, white bars) purified from breast milk collected from 4 HIV-
1-infected African mothers (women #1; #2; #3 and #4) (left scale). Specific
activities of purified breast milk immunoglobulins (black circles, right scale)
were calculated as the ratio of anti-gp160 activity (determined as optical density
of anti-gp160 by ELISA) out of the concentration of total immunoglobulin of
the same isotype (concentration of IgG or IgA in μg/ml), and are expressed in
arbitrary units.
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and differences in affinity between HIV-1 and its cellular
receptors. We further confirmed the role of envelope glycopro-
teins in HIV transcytosis by showing that purified polyclonal
antibodies to gp160 demonstrated major inhibitory properties of
transcytosis of HIV through a monolayer of HEC-1 cells. Since
glycosylation of gp160 was also shown to be critical for an
efficient interaction of HIV-1 with target cells, it could be
that polyclonal antibodies to gp160, in contrast to monoclonal
antibodies, recognize glycosylated epitopes implicated in at-
tachment of HIV-1 to the epithelial cell (Bolmstedt et al., 1996).
This latter hypothesis is in part supported by previous ob-
servation demonstrating that antibodies to GalCer, an alterna-
tive receptor recognizing carbohydrate residues of surface viral
glycoproteins (Bhat et al., 1991), are able to partially inhibit
HIV transcytosis (Bomsel, 1997) (in our hands, for example,
anti-GalCer antibodies were able to inhibit by 25% the
transcytosis of free HIV-1JR-CSF, data not shown). Finally, the
inhibition of transcytosis of cell-associated virus was always
less potent than that observed with the corresponding free virus,
suggesting that close contact between HIV-1-infected PBL and
the apical membrane of epithelial cells probably restricts access
of HIV-specific antibodies to their viral epitopes, thus affecting
their blocking capability.
The blocking capability on transcytosis of a panel of mono-
clonal antibodies directed against gp160 was investigated. We
selected antibodies recognizing major epitopes implicated in the
interaction between the gp160 and the CD4 and the co-receptors
CCR5 and CXCR4 (CD4 binding site, CD4i, V3, V4 and gp41).
Some of these antibodies (IgG1b12, 2F5 and 2G12) broadly
neutralize primary isolates of HIV-1 on PBMC in vitro. None of
the antibodies tested was able to block transcytosis of either
cell-free or cell-associated virus, even when the antibodies werepooled. The 2F5 monoclonal antibody was not able to inhibit
transcytosis of cell-free and cell-associated R5- as X4-tropic
HIV, in accordance with the previous observations reported by
Wolbank et al. (2003).
Secretory-IgA purified from colostrum of HIV-1-infected
women exhibited up to 250-times lower anti-gp160 activity
than did corresponding IgG. In spite of this lower anti-gp160
activity, S-IgA exhibited similar capability to inhibit transcy-
tosis of HIV-1 through a monolayer of epithelial cells. This
result is in favor of an important implication of molecular forms
or/and valence of anti-gp160 antibodies in inhibition of virus
transcytosis. Binding of IgG, dimeric IgA and pentameric IgM
polyclonal antibodies on HIV-1 leads to the coating of the viral
particle and probably to agglutination of virions at the surface of
epithelial cells. This hypothesis is consistent with the results of
Wolbank showing that polymeric 2F5 and 2G12, but not the
corresponding monomeric antibodies forms, interfere with HIV-
1 transcytosis across a mucosal epithelial layer (Wolbank et al.,
2003). Alfsen and colleagues have also shown that S-IgA spe-
cific to gp41 blocked cell-associated HIV-1 transcytosis (Alfsen
et al., 2001). Surprisingly, Wolbank and colleagues reported that
high avidity 2F5 IgM, that is the most efficient isotype for
agglutination, was less efficient than the corresponding dimeric
IgA antibody to inhibit transcytosis. It is likely that limited
inhibition induced by 2F5 IgM could be due to the inability of
this pentameric immunoglobulin to bind an epitope located at
the basis of gp41 ectodomain. In contrast to the limited
inhibitory effect of the 2F5 IgM, the 2G12 IgM recognizing a
conserved discontinuous motif on the outer domain of gp120
strongly inhibits HIV-1 transcytosis (Wolbank et al., 2003).
Taken together, these findings and our present results suggest
that surface agglutination of viral particles may participate to the
blocking effect observed with both polyclonal and polymeric
anti-gp160 immunoglobulins.
The present study demonstrates that anti-envelope antibody-
mediated inhibition of HIV-1 transcytosis through polarized
epithelial cells likely involves distinct molecular mechanisms
from those involved in neutralization. The use of the HIV
transcytosis inhibition assay by HIV-specific antibodies to assess
the mucosal antibody response to the virus, in highly exposed
persistently seronegative individuals and in individuals immu-
nized in vaccine trials, warrant further investigations regarding
mechanisms of the inhibition and correlates of protection.
Materials and methods
Reagents and antibodies
The following HIV-specific monoclonal antibodies were
obtained through the AIDSReagent Program, Division of AIDS,
NIAID, NIH: anti-HIV-1 gp41 monoclonal antibodies 2F5
(Buchacher et al., 1994; Purtscher et al., 1996, 1994) and 5F3
(Buchacher et al., 1994), anti-HIV-1 gp120 monoclonal
antibody 2G12 (Buchacher et al., 1994; Trkola et al., 1996)
from Dr Hermann Katinger, anti-HIV-1 gp120 monoclonal
antibodies F425 A1g8, F425 B4a1, F425 B4e8 (Cavacini et al.,
2003) and F105 (Cavacini et al., 1993; Posner et al., 1993, 1987,
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et al., 1998) from Drs Marshall Posner and Lisa Cavacini, anti-
HIV-1 gp120 monoclonal antibodies 17b (Kwong et al., 1998;
Sullivan et al., 1998;Wyatt et al., 1998) and 48d (Moore and Ho,
1993; Thali et al., 1993) from Dr James E. Robinson, anti-HIV-1
V3 monoclonal antibody IIIB-V3-21 (Laman et al., 1992) from
Dr Jon Laman, anti-HIV-1 gp41 monoclonal antibody 1577
(D'Souza et al., 1997; Evans et al., 1989) from Dr Morag
Ferguson, anti-HIV-1 gp120 monoclonal antibody IgG1b12
(Barbas et al., 1992; Burton et al., 1991, 1994; Roben et al.,
1994) from Drs Dennis Burton and Carlos Barbas. Human
polyclonal anti-gp160 antibodies were purified by immunoaffi-
nity from pooled sera of HIV-1 seropositive individuals. Anti-
human γ chain was purchased from SIGMA (Sigma Chemical
Co., St. Louis, USA). Sepharose beads to which gp160 (MN/
Lai) had been covalenlty bound were incubated for 1 h at 37 °C
with undiluted sera. The beads were washed and the antibodies
were eluted with 0.2 M glycin–HCl, pH 2.5. The pH of the
eluted fractions were immediately adjusted to 7.2 and the
reactivity of antibodies to gp160 tested by ELISA, as previously
described (Belec et al., 2001).
Secretory-IgA and IgG purification
Colostrum samples were collected at the Complexe Pédia-
trique of Bangui, Central African Republic, from four HIV-1-
infected mothers. The women were clinically asymptomatic
(stage A of the WHO classification) and gave an oral consent
for participation in the study. Breast milk samples were
centrifuged at 10,000 rpm for 5 min at 4 °C to separate lipids
and cells from the acellular fraction. IgG and S-IgA were then
purified by immunoaffinity using sepharose beads to which
anti- Fcγ or -Fcα (Perbio Science, Brebieres, France) had been
covalently bound. Concentrations of total IgG, S-IgA and IgM
were determined by ELISA, as previously described (Hocini et
al., 1997). Purity of the preparations and specific anti-HIV
activity of purified antibodies against gp160 were assessed by
ELISA.
Isolation of human lymphocytes
Peripheral blood mononuclear cells (PBMCs) were isolated
from buffy coats of healthy donors by centrifugation on Ficoll
gradients (Eurobio, Les Ulis, France). Cells were resuspended in
RPMI 1640 containing 10% fetal calf serum (FCS). After 1 h
incubation, non-adherent cells were removed and further
cultured for 48 h in fresh medium supplemented with PHA
and IL-2. Peripheral blood lymphocytes (PBLs) were then
washed and cultured in growth medium containing IL-2 for 24 h.
Viruses
HIV-1NDK, HIV-1VN44 and HIV-1JR-CSF strains were kindly
provided by Pr Françoise Barré-Sinoussi (Institut Pasteur, Paris,
France). HIV-1Ba-L, HIV-1Lai, HIV-189.6, HIV-1BruΔenv and
HIV-1NL43 were obtained from Dr Caroline Quillent-Grégoire
(Hôpital de La Pitié-Salpêtrière, Paris). All viral stocks weregrown in PHA-stimulated PBMCs and quantitated by p24
antigen measurement. Viral strains were titrated using HeLa-
CD4-LTR-β-gal cells (AIDS Reagent Program, Division of
AIDS, NIAID, NIH, Dr Michael Emerman) and the TCID50
were determined as described (Kimpton and Emerman, 1992).
Neutralization assay
Neutralization of HIV-1 isolates by monoclonal antibodies to
gp160 was assessed in PBLs by using an assay measuring the
reduction in p24 antigen synthesis by infected cells, as described
(Moog et al., 1997). Briefly, virus (0.2 to 1 ng of p24 antigen
corresponding to 100 to 1000 TCID50) was incubated with
monoclonal antibodies in triplicate in 96-well U-bottom culture
plates for 1 h at 37 °C. PHA-stimulated PBL (3×105 cells) were
added and incubation continued overnight. The cells were then
washed three times in RPMI and resuspended in 200 μl of fresh
medium supplemented with IL-2 (R&D Systems). Culture
supernatants (50 μl) were collected at days 3, 6 and 9 and
replaced with an equal volume of fresh growth medium.
Concentrations of p24 antigen in Triton X-100 lysates were
measured using a commercial antigen capture ELISA (Perkin
Elmer Life Sciences Inc, Courtaboeuf, France). Neutralization of
PBL infection was assessed by measuring the reduction in p24
antigen concentration in culture supernatants during the early
phase of virus production (i.e. days 3 to 6, depending on the viral
strain). Control wells contained virus that had been pre-
incubated with RPMI alone (no antibody). In some experiments,
additional controls included virus pre-incubated with irrelevant
IgG antibody.
Transcytosis assay
Inhibition of transcytosis was measured by means of an in
vitro system using a polarized monolayer of HEC-1 endometrial
epithelial cells (ATCC, Rockville, Maryland, USA) grown in
RPMI1640 10%FCS on a 0.4 μmpore polycarbonate permeable
support (Costar, Cambridge, MA), as previously described
(Becquart et al., 2000; Belec et al., 2001; Hocini et al., 2001).
After 7 to 9 days of culture, the tightness of the monolayer was
monitored by measuring resistance (N300 Ohms/cm2) at the
apical and basolateral poles of the cells (Ohmeter, Millicell,
Millipore). Free virions (5 ng of p24 antigen) were pre-incubated
for 1 h in 100 μl with different concentrations (up to 50 μg/ml) of
each monoclonal antibody. For cell-associated virus transcyto-
sis, HIV-1-infected PBL (2×106 cells) that had been washed
three-times were added to the apical chamber of the system
together with the monoclonal antibody to be tested at the desired
concentration (up to 50 μg/ml). Transcytosis was assessed after
4 h, 24 h and 48 h by measuring p24 antigen concentration in the
basal chamber. Inhibition of transcytosis was expressed as
percentage of p24 antigen recovered in the basal chamber in the
presence of antibodies, compared with the amount of p24
antigen recovered in the absence of antibody. A percentage of
inhibition superior to 25% (mean of the values obtained after
pre-incubation with irrelevant IgG plus 3 standard deviations)
was considered as significant.
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